Careers  |  Sign In  |  Register  |   Twitter

Free CME: Clinical Perspectives on the Role of the Kidney in the Pathphysiology of T2DM

Recent advances with novel orally administered SGLT2 cotransporter inhibitors offers a unique opportunity to address current unmet therapeutic needs and improve outcomes for the patient with T2DM. Optimal use of this new class of agents will require that clinicians understand the link between the kidney and glucose homeostasis, and the rationale for SGLT2 as a therapeutic target. This free CME activity will focus on the evidence that supports the safety and efficacy of this new class of agents, an understanding of its effects and adverse events so clinicians are able to confidently use these agents in practice.

Click here to participate in this free CME activity.